Spots Global Cancer Trial Database for solid tumour
Every month we try and update this database with for solid tumour cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers | NCT02648490 | Solid Tumour | HLX07 Acetaminophen dexamethasone diphenhydramine 5-HT3 inhibitor | 18 Years - | Henlix, Inc | |
| Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer | NCT01046461 | Solid Tumour Postoperative N... | Ramosetron, Apr... | 18 Years - 75 Years | Hallym University Medical Center | |
| Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours | NCT00697879 | Solid Tumor | CHR-3996 | 18 Years - | Chroma Therapeutics | |
| Study of AZD8931 in Patients With Advanced Solid Malignancies | NCT00637039 | Advanced Solid ... | AZD8931 | 18 Years - | AstraZeneca | |
| First in Human Study of AZD9592 in Solid Tumors | NCT05647122 | Advanced Solid ... Carcinoma Non-s... Head and Neck N... Colorectal Neop... | AZD9592 Osimertinib 5-Fluorouracil ... Leucovorin Bevacizumab | 18 Years - | AstraZeneca | |
| Phase 1 Study of KHK2898 in Subjects With Advanced Solid Tumors | NCT01516645 | Solid Tumour | KHK2898 | 18 Years - | Kyowa Kirin Co., Ltd. | |
| A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours | NCT04958226 | Solid Tumour | Capivasertib Midazolam | 18 Years - 130 Years | AstraZeneca | |
| Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile | NCT01226407 | Solid Tumour | CG200745 | 20 Years - 69 Years | CrystalGenomics, Inc. | |
| An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers | NCT02648490 | Solid Tumour | HLX07 Acetaminophen dexamethasone diphenhydramine 5-HT3 inhibitor | 18 Years - | Henlix, Inc | |
| Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | NCT04107142 | Colorectal Canc... Triple Negative... Sarcoma Nasopharyngeal ... Prostate Cancer Gastric Cancer | Adoptive Cell T... | 18 Years - | CytoMed Therapeutics Pte Ltd | |
| Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma | NCT01168752 | Cancer Neoplasms Solid Tumors Lymphoma | Debio 0932 | 18 Years - | Debiopharm International SA | |
| A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumours | NCT06130553 | Advanced Solid ... | AZD3470 | 18 Years - | AstraZeneca | |
| AZD6738 & Gemcitabine as Combination Therapy | NCT03669601 | Cancer | AZD6738 Gemcitabine | 16 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| First in Human Study of AZD9592 in Solid Tumors | NCT05647122 | Advanced Solid ... Carcinoma Non-s... Head and Neck N... Colorectal Neop... | AZD9592 Osimertinib 5-Fluorouracil ... Leucovorin Bevacizumab | 18 Years - | AstraZeneca | |
| Study of AZD8931 in Patients With Advanced Solid Malignancies | NCT00637039 | Advanced Solid ... | AZD8931 | 18 Years - | AstraZeneca | |
| Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | NCT04107142 | Colorectal Canc... Triple Negative... Sarcoma Nasopharyngeal ... Prostate Cancer Gastric Cancer | Adoptive Cell T... | 18 Years - | CytoMed Therapeutics Pte Ltd | |
| AZD6738 & Gemcitabine as Combination Therapy | NCT03669601 | Cancer | AZD6738 Gemcitabine | 16 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| AZD6738 & Gemcitabine as Combination Therapy | NCT03669601 | Cancer | AZD6738 Gemcitabine | 16 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours | NCT01489826 | Solid Tumour | Dexanabinol Cremophor | 18 Years - | e-Therapeutics PLC | |
| Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | NCT06208657 | Childhood Cance... Childhood Solid... Childhood Brain... Recurrent Cance... Refractory Canc... | Paxalisib, Irin... Pimasertib | 0 Years - 21 Years | Australian & New Zealand Children's Haematology/Oncology Group | |
| Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours | NCT00697879 | Solid Tumor | CHR-3996 | 18 Years - | Chroma Therapeutics | |
| CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia | NCT04891718 | Solid Tumour | MVC-101 Nivolumab MVC-101 + Nivol... | 18 Years - | Presage Biosciences | |
| A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours | NCT04958226 | Solid Tumour | Capivasertib Midazolam | 18 Years - 130 Years | AstraZeneca | |
| L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours | NCT02076620 | Advanced Solid ... Sarcoma, Breast... | L19TNFα Doxorubicin | 18 Years - | Philogen S.p.A. | |
| First in Human Study of AZD9592 in Solid Tumors | NCT05647122 | Advanced Solid ... Carcinoma Non-s... Head and Neck N... Colorectal Neop... | AZD9592 Osimertinib 5-Fluorouracil ... Leucovorin Bevacizumab | 18 Years - | AstraZeneca | |
| Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours | NCT02303028 | Solid Tumors | Topotecan and P... | 2 Years - 21 Years | The Hospital for Sick Children | |
| Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor | NCT02086721 | Solid Tumour | L19-IL2 | 18 Years - | Maastricht Radiation Oncology |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
